Altoida

Altoida is pioneering a new category in neurological diagnostics with its multi-modal digital biomarker platform. The company's core technology, the NeuroMarker Platform, uses AR tasks and sensor fusion on a smart tablet to capture hundreds of data points, aiming to detect cognitive decline earlier and more reliably than traditional pen-and-paper methods. Founded in 2017 and based on over two decades of research, Altoida is initially targeting MCI and Alzheimer's, with plans to expand into other CNS diseases. The platform is currently investigational and is being utilized in pharmaceutical research for clinical trial support.

Digital NeuroMarker Platform combining augmented reality (AR) tasks, sensor fusion (motion, touch, speech), and explainable AI to capture and analyze hundreds of digital biomarkers for objective cognitive and functional assessment.

Altoida competes with traditional pen-and-paper assessments, first-generation digital cognitive tests (e.g., computerized versions of old tests), and a growing field of digital biomarker companies like Cogstate, Linus Health, and others. Its key differentiators are the use of AR/sensor fusion for functional assessment, a strong foundation in neuroscience research, and a focus on explainable AI.